TESARO (TSRO) Price Target Raised to $38.00

TESARO (NASDAQ:TSRO) had its price objective hoisted by Bank of America from $35.00 to $38.00 in a report released on Tuesday, September 11th. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other analysts also recently weighed in on the company. Cann reiterated a buy rating and set a $83.00 price target on shares of TESARO in a report on Tuesday, September 4th. Barclays decreased their price target on TESARO from $60.00 to $56.00 and set an overweight rating for the company in a report on Monday, August 6th. Citigroup decreased their price target on TESARO from $100.00 to $85.00 and set a buy rating for the company in a report on Wednesday, August 29th. BidaskClub upgraded TESARO from a strong sell rating to a sell rating in a report on Thursday, September 6th. Finally, Zacks Investment Research downgraded TESARO from a hold rating to a sell rating in a report on Tuesday, July 3rd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $78.42.

NASDAQ TSRO traded up $1.10 on Tuesday, reaching $42.88. The company had a trading volume of 1,360,357 shares, compared to its average volume of 1,578,870. The company has a market capitalization of $2.14 billion, a price-to-earnings ratio of -4.68 and a beta of 1.00. TESARO has a fifty-two week low of $25.62 and a fifty-two week high of $125.78. The company has a quick ratio of 3.64, a current ratio of 4.11 and a debt-to-equity ratio of -29.71.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($3.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.66) by ($0.38). The company had revenue of $57.21 million during the quarter, compared to analyst estimates of $65.50 million. TESARO had a negative net margin of 180.29% and a negative return on equity of 285.30%. The business’s revenue for the quarter was up 94.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($2.82) earnings per share. Research analysts expect that TESARO will post -11.12 earnings per share for the current fiscal year.

In other news, Director Arnold L. Oronsky sold 10,000 shares of the stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $26.77, for a total transaction of $267,700.00. Following the transaction, the director now owns 12,479 shares of the company’s stock, valued at approximately $334,062.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 10,630 shares of company stock worth $290,424 in the last three months. Insiders own 33.70% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in TSRO. Commerzbank Aktiengesellschaft FI bought a new position in shares of TESARO during the 1st quarter worth about $344,000. Oppenheimer & Co. Inc. bought a new position in TESARO in the 1st quarter valued at about $220,000. SG Americas Securities LLC bought a new position in TESARO in the 1st quarter valued at about $110,000. Trexquant Investment LP bought a new position in TESARO in the 1st quarter valued at about $842,000. Finally, Victory Capital Management Inc. bought a new position in TESARO in the 1st quarter valued at about $686,000.

About TESARO

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Recommended Story: Leveraged Buyout (LBO) Explained

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply